{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-028372","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.426382+00:00","generated_at":"2026-05-26T02:54:10.201991+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Heron Q4 net income $3.6M; FY2024 rev $144.2M (+14%); guides 2025 rev $153-163M","bullets":["Q4 2024 GAAP net income of $3.6M; full-year 2024 adjusted EBITDA of $8.6M.","Full-year 2024 net revenue $144.2M (+14% YoY); Acute Care revenue up 57%, Oncology up 6%.","2025 guidance: net revenue $153-163M, adjusted EBITDA $0-8M.","U.S. District Court upheld CINVANTI patents against Fresenius Kabi; patents expire 2035.","Cash and investments $59.3M; ZYNRELEF VAN launched Dec 2024; Crosslink partnership."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-028372","json":"https://secwatch.observer/filing/0000950170-25-028372.json","markdown":"https://secwatch.observer/filing/0000950170-25-028372.md","text":"https://secwatch.observer/filing/0000950170-25-028372.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000095017025028372/0000950170-25-028372-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000095017025028372/hrtx-20250227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:54:10.201991+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}